Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study

References

• Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology and implications for the acute care setting. Pharm. Therapeut. 42, 180–188 (2017).
   Google Scholar
• Brucki SMD, Adoni T, Almeida CMO et al. Cannabinoids in neurology – position paper from scientific departments from Brazilian Academy of Neurology. Arq. Neuropsiquiatr. 79(4), 354–369 (2021).
   PubMed Web of Science ®Google Scholar
• Patel AD. Cannabinoids in neurologic illnesses. Neurol. Clin. 39(1), 231–241 (2021).
   PubMed Web of Science ®Google Scholar
• Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: therapeutic use in clinical practice. Int. J. Mol. Sci. 23(6), 3344 (2022).
   PubMed Web of Science ®Google Scholar
• Bhunia S, Kolishetti N, Arias AY, Vashist A, Nair M. Cannabidiol for neurodegenerative disorders: a comprehensive review. Front. Pharmacol. 989717 doi:10.3389/fphar.2022.989717 (2022).
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939–944 (1984).
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56(1), 33–39 (1999).
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32(6), 853–864 (2017).
   PubMed Web of Science ®Google Scholar
• Palace J. Making the diagnosis of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 71(Suppl. 2), ii3–ii8 (2001).
   PubMed Web of Science ®Google Scholar
• Biglan KM, Zhang Y, Long JD et al. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front. Aging Neurosci. 5, 12 (2013).
   PubMed Web of Science ®Google Scholar
• Gilman S, Low PA, Quinn N et al. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 163(1), 94–98 (1999).
   PubMed Web of Science ®Google Scholar
• Bott NT, Radke A, Stephens ML, Kramer JH. Frontotemporal dementia: diagnosis, deficits and management. Neurodegener. Dis. Manag. 4, 439–454 (2014).
   PubMedGoogle Scholar
• Arevalo-Rodriguez I, Smailagic N, Roqué I et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev. 2015(3), CD010783 (2015).
   PubMedGoogle Scholar
• Crawford S, Whitnall L, Robertson J, Evans JJ. A systematic review of the accuracy and clinical utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination-Revised in the diagnosis of dementia. Int. J. Geriatr. Psychiat. 27(7), 659–669 (2012).
   PubMed Web of Science ®Google Scholar
• Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS), Status and recommendations. Mov. Disord. doi:10.1002/mds.10473 (12 June 2003) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Dirks JF, Wunder J, Kinsman R, McElhinny J, Jones NF. A pain rating scale and a pain behavior checklist for clinical use: development, norms, and the consistency score. Psychother. Psychosom. 59(1), 41–49 (1993).
   PubMed Web of Science ®Google Scholar
• Tait RC, Chibnall JT, Krause S. The pain disability index: psychometric properties. Pain 1990(40), 171–182 (1990).
   Google Scholar
• Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 130(6), 1552–1565 (2007).
   PubMedGoogle Scholar
• Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 11(2), 136–142 (1996).
   PubMed Web of Science ®Google Scholar
• Wenning GK, Tison F, Seppi K et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord. 19(12), 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 14, 58 (2014).
   PubMed Web of Science ®Google Scholar
• Hoe J, Hancock G, Livingston G, Woods B, Challis D, Orrell M. Changes in the quality of life of people with dementia living in care homes. Alzheimer Dis. Assoc. Disord. 23(3), 285–290 (2009).
   PubMed Web of Science ®Google Scholar
• Houghton S, Wood L, Marais I, Rosenberg M, Ferguson R, Pettigrew S. Positive mental well-being. A validation of a Rasch-derived version of the Warwick-Edinburgh Mental Well-Being Scale. Am. Psychol. Assoc. Soc. Clin. Psychol. 24(3), 371–386 (2017).
   Google Scholar
• Krueger AB, Stone A. Progress in measuring subjective well-being: moving toward national indicators and policy evaluations. Science 346(6205), 42–43 (2014).
   PubMedGoogle Scholar
• Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther. 67(2), 206–207 (1987).
   PubMed Web of Science ®Google Scholar
• Panegyres PK. Stochasticity, entropy and neurodegeneration. Brain Sci. 12, 226 (2022).
   PubMed Web of Science ®Google Scholar
• Cassano T, Villani R, Pace L et al. From cannabis sativa to cannabidiol: promising therapeutic candidate for the treatment of neurodegenerative diseases. Front. Pharmacol. 11, 124 (2020).
   PubMed Web of Science ®Google Scholar
• Ortiz YT, McMahon LR, Wilkerson JL. Medicinal cannabis and central nervous system disorders. Front. Pharmacol. 13, 881810 (2022).
   PubMed Web of Science ®Google Scholar
• Therapeutic Goods Administration, Australian Government. Guidance for the use of medicinal cannabis in Australia (2017). Available at: www.tga.gov.au/resources/resource/guidance/guidance-use-medicinal-cannabis-australia-patient-information
   Google Scholar
• Zuardi AW, Crippa JAS, Hallak JEC et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 23, 979–983 (2009).
   PubMed Web of Science ®Google Scholar
• Buhmann C, Mainka T, Ebersback G, Gandor F. Evidence for the use of cannabinoids in Parkinson's disease. J. Neural Transm. 126, 913–924 (2019).
   PubMed Web of Science ®Google Scholar
• Peball M, Krismer F, Knaus HG et al. Non-motor symptoms in Parkinson's disease are reduced by nabilone. Ann. Neurol. 88(4), 712–722 (2020).
   PubMed Web of Science ®Google Scholar
• Hounie AG, Vasques MAA. Neurological improvement with medical cannabis in a progressive supranuclear palsy patient: a case report. Med. Cannabis Cannabinoids 2(2), 65–68 (2019).
   PubMedGoogle Scholar
• Ruthirakuhan M, Herrmann N, Andreazza AC et al. Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation. J. Geriatr. Psychiatry Neurol. 33(4), 175–184 (2020).
   PubMed Web of Science ®Google Scholar
• Kuharic DB, Markovic D, Brkovic T et al. Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev. 9(9), CD012820 (2021).
   PubMedGoogle Scholar
• Watt G, Karl T. In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer's disease. Front. Pharmacol. 8, 20 (2017).
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Wolfson T, Gamst A et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 184(10), 1143–1150 (2012).
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Sanders HP, Wright DE et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J. Neurol. Neurosurg. Psychiat. 76(12), 1664–1669 (2005).
   PubMed Web of Science ®Google Scholar
• Torres-Moreno MC, Papaseit E, Torrens M, Farré M. Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis. JAMA Netw. Open 1(6), e183485 (2018).
   PubMed Web of Science ®Google Scholar
• Gustavsen S, Søndergaard HB, Linnet K et al. Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis. Mult. Scler. Relat. Disord. 48, 102708 (2021).
   PubMed Web of Science ®Google Scholar
• Akinyemi E, Randhawa G, Longoria V, Zeine R. Medical marijuana effects in movement disorders, focus on Huntington disease: a literature review. J. Pharm. Pharm. Sci. 23, doi:10.18433/jpps30967 (2020).
   PubMed Web of Science ®Google Scholar
• Consroe P, Laguna J, Allender J et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40(3), 701–708 (1991).
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon Moreno JL, Garcia Caldentey J, Trigo Cubillo P et al. A double-blinded, randomized, cross-over, placebo-controlled pilot trial with Sativex in Huntington's disease. J. Neurol. 263(7), 1390–1400 (2016).
   PubMed Web of Science ®Google Scholar
• Leys F, Raccagni C, Sidoroff V, Seppi K, Fanciulli A, Wenning GK. Effects of self-administered cannabidiol in a patient with multiple system atrophy. Clin. Auton. Res. 30(4), 355–356 (2020).
   PubMed Web of Science ®Google Scholar
• Keehbauch J, Rensberry M. Effectiveness, adverse effects, and safety of medical marijuana. Am. Fam. Phys. 92(10), 856–863 (2015).
   PubMed Web of Science ®Google Scholar
• Yust-Katz S, Hershkovitz R, Gurevich T, Djaldetti R. Pain in extrapyramidal neurodegenerative diseases. Clin. J. Pain 33(7), 635–639 (2017).
   PubMed Web of Science ®Google Scholar
• Gopalakrishna G, Srivathsal Y, Kaur G. Cannabinoids in the management of frontotemporal dementia: a case series. Neurodegener. Dis. Manag. 11(1), 61–64 (2021).
   PubMed Web of Science ®Google Scholar
• Peprah K, McCormak S. Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines. Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada (7 July 2019).
   Google Scholar
• Haroutounian S, Ratz Y, Ginosar Y et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin. J. Pain 32(12), 1036–1043 (2016).
   PubMed Web of Science ®Google Scholar
• Schleider LB-L, Mechoulam R, Sikorin I, Naftali T, Novack V. Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: a prospective study. Front. Med. (Lausanne) 9, 827849 (2022).
   PubMed Web of Science ®Google Scholar
• Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Aust. J. Gen. Pract. 50(6), 345–350 (2021).
   PubMed Web of Science ®Google Scholar
• National Academies Collection. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press, WA, USA (2017).
   Google Scholar
• Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med. Rev. 18(6), 477–487 (2014).
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz J, Sagredo O, Pazos MR et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 75(2), 323–333 (2013).
   PubMed Web of Science ®Google Scholar
• Hounie A. Neurological improvement with medicinal cannabis in progressive supranuclear palsy patient: a case report. Presented at: International Conference on Natural Products and Traditional Medicine. Amsterdam, The Netherlands, 12, (13 July 2002).
   Google Scholar
• Sakai T, Mawatari S, Iwashita H, Goto I, Kuroiwa Y. Choreoacanthocytosis: clues to clinical diagnosis. Arch. Neurol. 38(6), 335–338 (1981).
   PubMedGoogle Scholar
• Bader B, Walker RH, Vogel M, Prosiegel M, McIntosh J, Danek A. Tongue protrusion and feeding dystonia: a hallmark of chorea-acanthocytosis. Mov. Disord. 25(1), 127–129 (2010).
   PubMed Web of Science ®Google Scholar
• Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Orphanet. J. Rare Dis. 6, 68 (2011).
   PubMed Web of Science ®Google Scholar
• Gedin F, Blomé S, Pontén M et al. Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain: a systematic review and meta-analysis. JAMA Netw. Open 5(11), e2243848 (2022).
   PubMed Web of Science ®Google Scholar